Treatment Strategies for Sarcopenia and Frailty

Rolland, Yves; Dupuy, Charlotte; Kan, Gabor Abellán van; Gillette, S.; Vellas, Bruno

doi:10.1016/j.mcna.2011.02.008

Cited by 95 publications

(78 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…115 Finally, it is important to recognize that genetic factors will only be one of the several contributors to sarcopenia-related traits and additional environmental and developmental factors must not be ignored when addressing future prevention and treatment strategies. 116,117 A consideration when examining the genetic aspects of skeletal muscle traits generally and sarcopenia in particular is that of a ' threshold ' level for these traits below which physical function is impaired. Once strength falls below a threshold value specific to that individual, physical function is impacted.…”

Section: Discussionmentioning

confidence: 99%

Genetic aspects of skeletal muscle strength and mass with relevance to sarcopenia

Roth¹

2012

BoneKEy Reports

View full text Add to dashboard Cite

Skeletal muscle is a highly heritable quantitative trait, with heritability estimates ranging 30 -85 % for muscle strength and 50 -80 % for lean mass. That strong genetic contribution indicates the possibility of using genetic information to individualize treatments for sarcopenia or even aid in prevention strategies through the use of genetic screening prior to the functional limitations. Though these possibilities provide the rationale for genetic studies of skeletal muscle traits, few genes have been identified that appear to contribute to variation in either skeletal muscle strength or mass phenotypes, and sarcopenia per se is remarkably understudied as a trait in this regard. This review examines the heritability of skeletal muscle traits, findings of linkage and genome-wide association analyses and impact of specific genes and gene-sequence variants on these traits as relevant to sarcopenia. Despite considerable work in the area, the genetic underpinnings of skeletal muscle traits remain largely unknown and the genetic aspects of sarcopenia are even less clear. Large-scale longitudinal clinical studies relying on advanced genome-wide association and other techniques are needed to provide further insights into the genes and gene variants that contribute to skeletal muscle strength and mass, and ultimately to susceptibility to sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Genetic aspects of skeletal muscle strength and mass with relevance to sarcopenia

Roth¹

2012

BoneKEy Reports

View full text Add to dashboard Cite

show abstract

“…Due to the role of poor appetite and resulting poor nutritional intake in the development of frailty, nutritional strategies have been highlighted as an important first step in treating frailty and pre-frailty [89]. In frail older people, intake of dietary energy and protein be can insufficient to meet requirements, and muscle stores of carbohydrate and protein, as well as adipose tissue are broken down and utilized to maintain the energy supply to essential cells of the body and maintain metabolism [90].…”

Section: Treatment Strategiesmentioning

confidence: 99%

“…There are a number of potential nutritional strategies to improve nutritional intake and build up nutrient stores to improve the potential to withstand future physiological stressors [89,93].…”

Section: Treatment Strategiesmentioning

confidence: 99%

Musculoskeletal health, frailty and functional decline

Milte

Crotty

2014

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

Frailty in older people is associated with a vulnerability to adverse events. While ageing is associated with a loss of physiological reserves identifying those with the syndrome of frailty has the potential to assist clinicians tailor treatments to those at risk of future decline into disability with increased risk of complications, morbidity and mortality. Sarcopenia is a key component of the frailty syndrome and on its own puts older people at risk of fragility fractures however the clinical syndrome of frailty affects musculoskeletal and non musculoskeletal systems. Hip fractures are becoming a prototype condition in the study of frailty. Following a hip fracture many of the interventions are focused on limiting mobility disability and restoring independence with activities of daily living but there are multiple factors to be addressed including osteoporosis, sarcopenia, delirium, weight loss. Established techniques of geriatric evaluation and management allow systematic assessment and intervention on multiple components by multidisciplinary teams and deliver the best outcomes. Using the concept of frailty to identify older people with musculoskeletal problems as at risk of a poor outcome assists in treatment planning and is likely to become more important as effective pharmacological treatments for sarcopenia emerge. This review will focus on the concept of frailty and its relationship with functional decline, as well as describing its causes, prevalence, risk factors and potential clinical applications and treatment strategies. Key wordsFragility fracture, frailty, functional decline, screening, older adult, exercise therapy, dietary therapy Word count 9,401 words (word limit=9,400)

show abstract

“…It is indeed crucial to move ahead in the field and achieve agreement about how to measure sarcopenia in a standardized and validated way. This step is crucial for paving the way to the development and future use of interventions directed against the age-related skeletal muscle decline 13) .…”

Section: What Is Sarcopenia?mentioning

confidence: 99%

Physical Frailty and Sarcopenia: Development of a Framework for Supporting Interventions Against Incident Mobility Disability

Cesari

2017

Ann Geriatr Med Res

View full text Add to dashboard Cite

In 2014, the Innovative Medicines Initiative funded a 48-million Euros project entitled "Sarcopenia and Physical fRailty IN older people: multi-componenT Treatment strategies" (SPRINTT). The SPRINTT consortium federates partners from academia, industry, and the private sector to address an important gap in the geriatric field: the lack of a standardized and clinically relevant definition of sarcopenia. In particular, the SPRINTT project aims to involve all major stakeholders in the framing of a skeletal muscle-specific risk profile that exposes the individual at risk of negative health-related outcomes (in particular, disability), is amenable to benefiting from preventive interventions, and meets the standards requested by regulatory agencies. During the first year of activity, the SPRINTT consortium has implemented a "Physical Frailty & Sarcopenia" (PF&S) condition that considers existing evidence and regularly exchanges information with the European Medicines Agency. This condition is currently the study objective of a 3-year randomized controlled trial in multiple countries across Europe. The trial aims to verify whether a multicomponent intervention (based on physical activity and nutritional counseling) can prevent the onset of mobility disabilities in community-dwelling older persons with PF&S. The present article provides an overview of the SPRINTT background and rationale and explains the details of the PF&S condition.

show abstract

Treatment Strategies for Sarcopenia and Frailty

Cited by 95 publications

References 98 publications

Genetic aspects of skeletal muscle strength and mass with relevance to sarcopenia

Genetic aspects of skeletal muscle strength and mass with relevance to sarcopenia

Musculoskeletal health, frailty and functional decline

Physical Frailty and Sarcopenia: Development of a Framework for Supporting Interventions Against Incident Mobility Disability

Contact Info

Product

Resources

About